As Alexion fields applications for ALXN1210, a rival aims for the crown with head-to-head PhIII; Novo hands NBE €20M
→ Alexion $ALXN has filed for a European approval for ALXN1210, one in a series of applications that followed the recent application in the US. Designed to succeed their franchise drug Soliris, the drug has some advantages in treating PNH, but didn’t prove superior in pivotal tests. Interestingly, earlier this week one of Alexion’s rivals, Apellis $APLS, started a head-to-head Phase III study comparing its APL-2 with Soliris, one of the world’s most expensive therapies. Apellis CEO Cedric Francois noted: “We believe there’s an unmet medical need to bring patients with PNH a better treatment option that will provide broad hematological correction and better quality of life than the current standard of care.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.